Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) agreed to sell a total equity stake of 55% in Shanghai Fujian Equity Investment Fund Management to three parties for around 26.5 million yuan, an April 11 filing with the Hong Kong bourse said.
Of this, 29%, 25.9% and 0.1% equity interests were sold to controlling shareholder Shanghai Fosun High Technology (Group), Li Fan, and executive director Guan Xiaohui for around 14 million yuan, 12.5 million yuan, and 48,254 yuan, respectively.
Following completion, the company holds a 45% equity stake in the target company, which engages mainly in equity investment management, investment management, and investment consultancy.
The pharmaceutical firm will use proceeds from the sale for working capital.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。